Splash Pharmaceuticals

Executive Summary

Splash Pharmaceuticals is a clinical-stage biotechnology company focused on targeting the CD44 pathway to develop novel therapies for oncology and arthritis. The company’s lead candidate, SPL-108, has been evaluated in multiple clinical trials involving over 100 human subjects, demonstrating early safety and tolerability. Positioned as a premier player in CD44-targeted therapy, Splash aims to address significant unmet needs in solid tumors and inflammatory diseases. With a robust preclinical and clinical foundation, the company is poised to advance SPL-108 into later-stage clinical development, potentially unlocking the therapeutic potential of CD44 modulation.

Upcoming Catalysts (preview)

• Q3 2026Topline Phase 1 data readout for SPL-108 in oncology70% success
• Q1 2027Initiation of Phase 2 trial for SPL-108 in rheumatoid arthritis65% success
• Q2 2026Presentation of clinical data at a major medical conference (e.g., ASCO)80% success